Phenotypes of Bronchopulmonary Dysplasia
Bronchopulmonary dysplasia (BPD) is the most common chronic morbidity in preterm infants. In the absence of effective interventions, BPD is currently a major therapeutic challenge. Several risk factors are known for this multifactorial disease that results in disrupted lung development. Inflammation...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-08-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/21/17/6112 |
| _version_ | 1797555755498340352 |
|---|---|
| author | Shih-Hsin Wang Po-Nien Tsao |
| author_facet | Shih-Hsin Wang Po-Nien Tsao |
| author_sort | Shih-Hsin Wang |
| collection | DOAJ |
| description | Bronchopulmonary dysplasia (BPD) is the most common chronic morbidity in preterm infants. In the absence of effective interventions, BPD is currently a major therapeutic challenge. Several risk factors are known for this multifactorial disease that results in disrupted lung development. Inflammation plays an important role and leads to persistent airway and pulmonary vascular disease. Since corticosteroids are potent anti-inflammatory agents, postnatal corticosteroids have been used widely for BPD prevention and treatment. However, the clinical responses vary to a great degree across individuals, and steroid-related complications remain major concerns. Emerging studies on the molecular mechanism of lung alveolarization during inflammatory stress will elucidate the complicated pathway and help discover novel therapeutic targets. Moreover, with the advances in metabolomics, there are new opportunities to identify biomarkers for early diagnosis and prognosis prediction of BPD. Pharmacometabolomics is another novel field aiming to identify the metabolomic changes before and after a specific drug treatment. Through this “metabolic signature,” a more precise treatment may be developed, thereby avoiding unnecessary drug exposure in non-responders. In the future, more clinical, genetic, and translational studies would be required to improve the classification of BPD phenotypes and achieve individualized care to enhance the respiratory outcomes in preterm infants. |
| first_indexed | 2024-03-10T16:52:06Z |
| format | Article |
| id | doaj.art-a92d9cfbfc0c447e8e024d66f24f3941 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T16:52:06Z |
| publishDate | 2020-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-a92d9cfbfc0c447e8e024d66f24f39412023-11-20T11:16:45ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-08-012117611210.3390/ijms21176112Phenotypes of Bronchopulmonary DysplasiaShih-Hsin Wang0Po-Nien Tsao1Department of Pediatrics, Far Eastern Memorial Hospital, New Taipei City 22060, TaiwanDepartment of Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei 100225, TaiwanBronchopulmonary dysplasia (BPD) is the most common chronic morbidity in preterm infants. In the absence of effective interventions, BPD is currently a major therapeutic challenge. Several risk factors are known for this multifactorial disease that results in disrupted lung development. Inflammation plays an important role and leads to persistent airway and pulmonary vascular disease. Since corticosteroids are potent anti-inflammatory agents, postnatal corticosteroids have been used widely for BPD prevention and treatment. However, the clinical responses vary to a great degree across individuals, and steroid-related complications remain major concerns. Emerging studies on the molecular mechanism of lung alveolarization during inflammatory stress will elucidate the complicated pathway and help discover novel therapeutic targets. Moreover, with the advances in metabolomics, there are new opportunities to identify biomarkers for early diagnosis and prognosis prediction of BPD. Pharmacometabolomics is another novel field aiming to identify the metabolomic changes before and after a specific drug treatment. Through this “metabolic signature,” a more precise treatment may be developed, thereby avoiding unnecessary drug exposure in non-responders. In the future, more clinical, genetic, and translational studies would be required to improve the classification of BPD phenotypes and achieve individualized care to enhance the respiratory outcomes in preterm infants.https://www.mdpi.com/1422-0067/21/17/6112bronchopulmonary dysplasiametabolomicspretermcorticosteroidsphenotypehyperoxia |
| spellingShingle | Shih-Hsin Wang Po-Nien Tsao Phenotypes of Bronchopulmonary Dysplasia International Journal of Molecular Sciences bronchopulmonary dysplasia metabolomics preterm corticosteroids phenotype hyperoxia |
| title | Phenotypes of Bronchopulmonary Dysplasia |
| title_full | Phenotypes of Bronchopulmonary Dysplasia |
| title_fullStr | Phenotypes of Bronchopulmonary Dysplasia |
| title_full_unstemmed | Phenotypes of Bronchopulmonary Dysplasia |
| title_short | Phenotypes of Bronchopulmonary Dysplasia |
| title_sort | phenotypes of bronchopulmonary dysplasia |
| topic | bronchopulmonary dysplasia metabolomics preterm corticosteroids phenotype hyperoxia |
| url | https://www.mdpi.com/1422-0067/21/17/6112 |
| work_keys_str_mv | AT shihhsinwang phenotypesofbronchopulmonarydysplasia AT ponientsao phenotypesofbronchopulmonarydysplasia |